Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1038/srep04645

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12152931

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids

James A. Ankrum1,2, Riddhi G. Dastidar1, Joon Fai Ong1, Oren Levy1 & Jeffrey M. Karp1,2,3

1Center for Regenerative Therapeutics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA, 2Harvard-MIT Division of Health Sciences & Technology, Cambridge, MA 02139, USA, 3Harvard Stem Cell Institute, 1350 Massachusetts Avenue, Cambridge, MA 02138, USA.

Inadequate immunomodulatory potency of mesenchymal stem cells (MSC) may limit their therapeutic efficacy. We report glucocorticoid steroids augment MSC expression and activity of indoleamine-2,3-dioxygenase (IDO), a primary mediator of MSC immunomodulatory function. This effect depends on signaling through the glucocorticoid receptor and is mediated through up-regulation of FOXO3. Treatment of MSCs with glucocorticoids, budesonide or dexamethasone, enhanced IDO expression following IFN-γ stimulation in multiple donors and was able to restore IDO expression in over-passaged MSCs. As IDO enhancement was most notable when cells were continuously exposed to budesonide, we engineered MSC with budesonide loaded PLGA microparticles. MSC efficiently internalized budesonide microparticles and exhibited 4-fold enhanced IDO activity compared to budesonide preconditioned and naive MSC, resulting in a 2-fold improvement in suppression of stimulated peripheral blood mononuclear cells in an IDO-dependent manner. Thus, the augmentation of MSC immune modulation may abrogate challenges associated with inadequate potency and enhance their therapeutic efficacy.

The potential of mesenchymal stem cells (MSCs) to ameliorate inflammation arising from numerous diseases has been established in preclinical animal models leading to hundreds of MSC clinical trials1-4. While MSCs appear to be beneficial in several disease models, treatment of patients has led to highly variable outcomes. For example, subsets of patients with graft versus host disease (GVHD) have responded remarkably well to MSC therapy with at least temporary resolution of symptoms5-7, while for others their prognosis is unaltered8,9. Factors limiting MSC therapy include insufficient and variable immunomodulatory potency8,9, dependence on in vivo activation by host inflammatory mediators to achieve MSC immunomodulation10-12, and limited MSC persistence13. Substantial batch to batch variability in MSC secretome, in vitro immunomodulatory potential14,15, and treatment efficacy linked to differences in MSC donors16,17, tissue of origin18,19, and passages20-22 have recently been reported. Furthermore, limited persistence shortens the therapeutic window in which MSCs modulate inflammatory responses via secretion of growth factors and cytokines, release of exosomes, or activity of immunomodulatory enzymes such as iNOS and IDO. Thus, techniques to augment and control the potency of MSC are needed for a therapeutic effect to be exerted within a short therapeutic window. We hypothesize that engineering MSCs to maximize and sustain immunosuppressive potential will enable the generation of enhanced cell-based therapies and eliminate the need to contemplate from which tissue or donor MSCs should be derived.

One of the primary factors mediating MSC immune suppression is the tryptophan depleting enzyme indoleamine-2,3-dioxygenase (IDO). Inhibiting IDO with 1-methyl-DL-tryptophan (1-MT) in human MSCs abrogates their immunosuppressive potential in peripheral blood mononuclear cell (PBMC) co-cultures7,13. In contrast to secreted factors implicated in MSC immune suppression such as PGE27,11-14 or TSG-68,10, IDO is an intracellular enzyme. Specifically, IDO is the first and rate-limiting enzyme involved in degradation of tryptophan down the kynurenine pathway and is predominately expressed in antigen presenting cells (APCs) in response to type 1 interferons15. Additionally, human MSCs have been shown to have IDO-dependent antimicrobial effects against staphylococcus aureus, staphylococcus epidermis, and toxoplasma gondii16. As in APCs, expression of IDO in MSCs occurs in response to inflammation, induced by exposure to interferon-γ (IFN-γ). Both the depletion of tryptophan and the generation of kynurenine byproducts have potent suppressive effects on immune cells15,17. IDO has been implicated in promoting both physiological and pathological tolerance. IDO expressed by cells in the placenta is responsible for fetal tolerance, and inhibition of IDO by the inhibitor...
1-methyl-tryptophan (1-MT) results in allograft rejection of the fetus. More recently, IDO has been found to be overexpressed in solid tumors, promoting tolerance toward tumor antigens and tryptophan depletion has been shown to suppress T-cell proliferation through activation of general control non-depressing 2 (GCN2) kinase. In addition to tryptophan depletion, IDO generates tryptophan catabolites that inhibit the proliferation of activated T-cells and induce naïve T-cells to become FoxP3+ T-regulatory cells. Due to the role of IDO as a negative regulator of inflammation and inducer of tolerance, the level and regulation of its expression is of great interest for maternal-fetal tolerance, tumor immunity, allergy, autoimmune disease, transplant tolerance, and MSC therapy. Unfortunately, the level of MSC IDO expression varies significantly between donors and between MSC tissue sources leading to variability in MSC's ability to suppress activated T-cells.

As elevated IDO activity correlates with enhanced suppression of T-cell activation and proliferation, augmenting MSC IDO levels should increase their immunomodulatory potency. Interestingly, IDO expression in macrophages and dendritic cells has been shown to be augmented by exposure to glucocorticoid steroids mediated in part through cell-cell contact signaling through interactions between the glucocorticoid-induced tumor necrosis factor receptor related protein (GITR) and its ligand (GITRL). Similarly, augmented IDO expression following glucocorticoid steroid treatment has also been observed in astrocytes, although the mechanism of steroid enhanced IDO activity is not known. While MSCs are frequently administered to patients with GvHD who are already receiving glucocorticoid steroids, the impact of glucocorticoid steroids on MSCs, and specifically on their IDO activity, has not been investigated.

Herein, we report that budesonide, a glucocorticoid steroid with fewer systemic effects than dexamethasone, significantly boosts MSC IDO activity and immunosuppressive phenotype and we introduce a cell engineering strategy to sustain MSC therapeutic potency without requiring soluble budesonide. Specifically, we observe that budesonide-treated MSCs show similar metabolic activity, viability, and morphology to untreated MSCs, yet exhibit a favorable shift in their expression of immunogenic and immunosuppressive factors. In addition to enhancing IFN-γ induced IDO expression and activity, BUD treatment also significantly reduced MSC expression of MHC molecules. We found that combined exposure to both budesonide and inflammatory cues resulted in the highest levels of IDO expression, as IDO is only expressed in response to inflammatory signaling. Additionally, the response was broadly applicable to other glucocorticoids, as dexamethasone produced a similar IDO response, and blocking the glucocorticoid receptor inhibited the enhanced IDO expression. To engineer cells with enhanced and sustained immunosuppressive potency that can be activated upon entering an inflammatory environment without requiring systemic administration of immunosuppressant drugs, we utilized a particle engineering approach. Budesonide loaded microparticles were efficiently internalized by MSCs and resulted in significant enhancement of MSC IDO expression and activity, similar to soluble budesonide. In vitro co-culture assays with PBMCs revealed the engineered MSCs could be activated in situ in response to IFN-γ produced by PBMCs. Engineered MSC suppression of PBMCs was enhanced further by pre-activating MSCs with IFN-γ to increase expression of IDO prior to the initiation of the PBMC co-cultures. Addition of the IDO inhibitor 1-MT completely abolished the suppressive properties of the engineered MSCs, implicating IDO as a key immunosuppressive factor. We believe this engineering strategy could be used to augment MSC potency, resulting in enhanced cell-based therapies.

**Results**

**Impact of budesonide on MSC viability and morphology.** Glucocorticoid steroids are commonly prescribed anti-inflammatory drugs that have diverse effects on immune cells, however their effect on MSC immunogenicity and immunomodulatory potential has not been thoroughly examined. Glucocorticoid steroids exert their effects through binding cytoplasmic glucocorticoid receptors and translocating to the nucleus where they bind glucocorticoid responsive elements (GREs), resulting in promotion or suppression of gene expression. As such, glucocorticoid steroids, such as budesonide, have variable effects on cells of different origins, including growth inhibition, suppression of MHC expression, and induction of IDO.

To examine if budesonide alters MSC potency without negatively impacting MSC phenotype, MSCs were exposed to 0.001–100 μM budesonide for 24–72 hours. Metabolic activity, as assessed by XTT, was not significantly affected by budesonide treatment for 24, 48, or 72 hours over the dosage range tested (Fig. 1A). Flow cytometry analysis revealed no significant changes in MSC viability as evidenced by dual negative staining for Annexin-V and propidium iodide after 72 hours of budesonide exposure (Fig. 1B). Phase contrast imaging of treated cells did not show any appreciable impact of budesonide on the morphology of MSCs after 48 hours of budesonide exposure (Fig. 1C). In addition, MSCs treated with budesonide for 48 hours showed no evidence of increased cell death when evaluated for double strand breaks by TUNEL staining (Fig. 1D). Collectively these data show MSC metabolic activity, morphology, proliferation, and viability were preserved over a wide range of budesonide concentrations.

**Impact of budesonide on MSC immunophenotype.** Next we analyzed the effect of budesonide on MSC expression of MHC I and MHC II molecules. The naturally low expression of MHC I, lack of MHC II, and failure of MSC to elicit hyperacute rejection upon infusion has been used to justify the use of unmatched allogeneic MSCs in animal models and clinical trials. However, upon exposure to an inflammatory environment, expression of both MHC molecules increases. Interestingly, glucocorticoids have been shown to reduce expression of MHC molecules in many cell types. Expression of class I and class II MHC molecules, HLA-ABC and HLA-DR respectively, were examined to investigate budesonide’s impact on MSC immunophenotype before and after IFN-γ stimulation. MSCs were exposed to vehicle (DMSO) or budesonide for 24 hours after which media was changed to include IFN-γ and the cells were cultured for an additional 48 hours prior to antibody staining and flow cytometry analysis. Cells in the ‘drug preconditioning’ group were exposed to budesonide only during the first 24 hours while cells in the ‘drug sustained’ group were exposed to budesonide for the duration of the experiment (Fig. 2A). Figure 2B shows that MSC expression of HLA-ABC was reduced by over 50% for all doses of budesonide in both the precondition and drug sustained groups (p < 0.001). Following exposure to 100 μM budesonide, stimulation with IFN-γ reduced HLA-ABC expression by only ~15% (not significant (NS), Fig. 2B, C). Budesonide treatment did not result in any increase of HLA-DR expression in unstimulated conditions or decrease in HLA-DR in stimulated conditions except for the 100 μM treated group. Preconditioning with 100 μM budesonide reduced IFN-γ induced HLA-DR expression by 11% (NS) while sustained exposure resulted in a 40% reduction (p < 0.001, Fig. 2D,E).

**Impact of budesonide on MSC IDO activity.** MSC immunosuppressive potential was evaluated following exposure to budesonide through assessment of IDO protein content and activity. Following treatment of MSCs with 1 μM budesonide for 24 hours, MSCs were additionally exposed to 100 ng/ml IFN-γ for 48 hours (Fig. 3A). MSCs were collected, lysed, and IDO protein content was analyzed by western blot. Budesonide treatment alone did not result in any increase in IDO protein content over untreated MSCs (Fig. 3B). IFN-γ stimulation resulted in increased IDO content in both untreated
and budesonide treated MSCs, with budesonide treated cells containing significantly more IDO than untreated controls. To determine the extent to which budesonide could enhance MSC IDO expression, IDO content of MSCs from multiple donors and passages was analyzed with and without budesonide treatment. Enhancement in IDO expression following budesonide exposure was observed in MSCs from multiple donors, regardless of the baseline level of IDO expression (no budesonide treatment) for each donor (Fig. 3C). In addition, high passage, P8, MSCs treated with budesonide expressed IDO at levels greater or similar to untreated P5 MSCs (Fig. 3D). Interestingly, IDO expression was most significantly enhanced when budesonide was continuously present versus simply pretreated (Fig. 3E,F). To demonstrate the ability to enhance the immunomodulatory potency of MSCs with poor immunosuppressive potential, donor #7083, which had the lowest baseline IFN-γ inducible IDO expression (no budesonide...
treatment) of the three donors, was used for all subsequent experiments. As the immunomodulatory function of IDO is dependent on its activity as an enzyme, an enzymatic activity assay was performed. Specifically, MSCs were grown according to the protocol depicted in Fig. 3A, collected, lysed to isolate IDO from the cytoplasm, and the quantity of L-kynurenine produced was measured by a colorimetric assay. Exposure to budesonide had a dramatic effect on MSC’s IDO activity. While IDO expression naturally increases upon stimulation with IFN-γ, additional conditioning by budesonide resulted in an over 4-fold increase in IDO activity (Fig. 3G).

Mechanism of IDO augmentation. To begin to elucidate the mechanism of budesonide-mediated enhancement of MSC IDO expression, we examined the timing and activation of intracellular pathways likely to be involved. Elevated IDO levels were first detected by western blot 24 hours after IFN-γ exposure (Fig. 4A,B), consistent with previous reports that show IFN-γ stimulates new transcription of IDO mRNA in MSCs6. Furthermore, the effect does not appear to be mediated through increased sensitivity to IFN-γ, as the timing and degree of Stat-1 phosphorylation between untreated (Fig. 4A) and budesonide treated (Fig. 4B) MSCs were

Figure 2 | Impact of budesonide on relative MHC molecule expression (A) Timing of MSC exposure to budesonide and IFN-γ in the Drug Precondition and Drug Sustained groups. Flow cytometric analysis of (B,C) HLA-ABC and (D,E) HLA-DR surface expression of MSCs. MSC were plated in 25 cm² flasks (100,000 MSC/flask) with media containing vehicle or budesonide and were either stimulated with IFN-γ or left unstimulated. MSC were then cultured an additional 48 hours without budesonide (Drug Precondition) or with budesonide (Drug Sustained). (B,D) show mean fluorescence intensity (MFI) for each condition. (Bars are mean ± SEM, One-way ANOVA with Bonferroni correction for multiple comparisons, n = 3, *p < 0.001 compared to untreated control). (C,E) show representative flow cytometry plots including isotype controls.
nearly identical. In addition, the pattern of immediate increase in phosphorylated Stat-1 following IFN-γ exposure and an increase in total Stat-1 following 24 hours of IFN-γ treatment is consistent with patterns described in the literature for human cell lines. Next we examined if budesonide was exerting its effect on IDO expression through the glucocorticoid receptor. Blocking the glucocorticoid receptor with 2 μM of RU486 reversed budesonide’s enhancing effect on IDO expression back to baseline levels (Fig. 4C). This data suggests budesonide mediated enhancement of IDO is dependent on the glucocorticoid receptor. Consistent with this observation is the finding that treatment with either budesonide or dexamethasone, both glucocorticoid steroids, results in similar enhancement in IDO expression (Fig. 4D). Interestingly, the promoter region for the IDO gene does not contain any known glucocorticoid responsive elements (GRE). Thus, steroid enhancement of IDO is likely mediated through up-regulation of a glucocorticoid responsive intermediary that enhances the transcription of IDO. Therefore we looked for transcription factors known to bind the IDO promoter that are also sensitive to glucocorticoid steroids. IDO has previously been reported to be promoted by FOXO3, a transcription factor which has recently been shown to be a target of the glucocorticoid receptor. To determine FOXO3’s role in budesonide-mediated enhancement of MSC IDO, we performed siRNA knockdown experiments. MSCs were transfected with FOXO3 siRNA or scramble siRNA as a control and then treated with budesonide for 24 hours, after which cells were treated with IFN-γ. FOXO3 expression was measured 6 hours after IFN-γ addition (preliminary experiments revealed peak FOXO3 content at this time point) and IDO was measured 30 hours after IFN-γ addition. Transfection of MSCs with FOXO3 siRNA resulted in
nearly complete inhibition of FOXO3 (Fig. 4E) and reverted budesonide treated MSC IDO expression (Fig. 4F) and activity (Fig. 4G) back to the level of untreated MSCs. Collectively this data suggests budesonide’s effect on MSC IDO expression is mediated by glucocorticoid-induced expression of FOXO3 which then acts as a genomic enhancer to augment IDO expression.

Establishing prolonged control of MSCs. We next sought to examine if we could prolong enhanced MSC IDO activity without the need for continuous exposure to soluble budesonide. Glucocorticoid steroids are commonly used clinically and potentially could be co-administered with MSCs, however, their lack of specificity causes them to have numerous off-target effects that can be detrimental to the overall health of a patient27,36,37. Thus, developing a method to control MSC phenotype without requiring co-administration of systemic glucocorticoid steroids thereby minimizing systemic exposure is desirable. To achieve prolonged control of MSC IDO activity we drew from our prior experience loading MSCs with drug loaded poly(lactic-co-glycolic acid) (PLGA) microparticles38. Previously we have shown that using the particle-in-cell approach, 1 μm particles can be efficiently internalized into MSCs and remain stable for at least 7-days during which time, small molecule drugs can be released to influence the phenotype of cells38–40.

Budesonide microparticles, 1 μm in diameter with low polydispersity were formulated to control MSC IDO activity (Fig. 5A,B). Surface modification of the particles with poly-L-Lysine resulted in a...
IDO enzymatic activity over Blank-PLGA modified and unmodified

Finally, BUD-PLGA modified MSCs exhibited a 5-times augmentation in IDO expression and activity within cell lysates. MSCs were modified with either BUD-PLGA or Blank-PLGA particles overnight, allowed to rest 24 hours, and then stimulated with IFN-γ to ensure rapid release of the drug during the first week following MSC particle modification. Release kinetic experiments were performed, revealing a burst release of 20% of total drug in the first 12 hours followed by a continuous release, with ~80% of total drug released by day 10 (Fig. 5C). MSC internalization of particles was optimized as previously described by modulating the size and zeta-potential of the particles. MSC association with 1 μm PLGA particles coated with poly-L-Lysine was confirmed by flow cytometry showing nearly all MSCs associated with particles (Fig. 5D). Confocal imaging revealed PLGA particles were not merely associating with the outer plasma membrane, but internalized (Fig. 5E). MSC’s were engineered with BUD-Particles without impacting cell viability (Fig. 5F).

To test if the intracellular release of budesonide from PLGA particles would work similarly to soluble budesonide, we examined the expression and activity of IDO within cell lysates. MSCs were modified with either BUD-PLGA or Blank-PLGA particles overnight, allowed to rest 24 hours, and then stimulated with IFN-γ for 48 hours, after which cells were harvested for analysis (Fig. 6A). As with soluble budesonide, BUD-PLGA particle modification significantly increased the content of IDO in MSC lysate (Fig. 6B). In addition, when compared head to head, BUD-PLGA particle modified MSCs expressed higher levels of IDO than MSCs simply pretreated with soluble budesonide before IFN-γ activation (Fig. 6C). Finally, BUD-PLGA modified MSCs exhibited a 5× augmentation in IDO enzymatic activity over Blank-PLGA modified and unmodified MSCs (Fig. 6D), an effect similar to what was observed with soluble budesonide (Fig. 3G).

Enhanced immunosuppressive properties in vitro. To test our hypothesis that enhanced IDO activity would lead to enhanced immunosuppression, MSCs were co-cultured with CD3/CD28 Dynabead activated PBMCs. BUD-Particle modified MSCs showed significantly enhanced suppression over budesonide preconditioned MSCs, which showed no advantage over naïve MSCs (Fig. 6E). To determine the degree of BUD-Particle modified MSC enhancement over naïve MSCs, ratiometric MSC:PBMC co-cultures were established by fixing the number of PBMCs in each well and varying the number of MSCs plated to achieve MSC:PBMC ratios of 1:4, 1:8, or 1:16. Unmodified, Blank-Particle modified, and BUD-Particle modified MSCs each suppressed PBMC proliferation in a cell-dose dependent manner. However, BUD-Particle MSCs showed enhanced suppression of PBMCs at all ratios tested as evidenced by reduced proliferation (Fig. 7C,D) and decreased IFN-γ production (Fig. 7E). Impressively, BUD-Particle MSC co-cultures at 1:8 and 1:16 ratios were as effective at suppressing PBMC proliferation and IFN-γ secretion as native MSCs at 1:4 and 1:8 ratios, respectively. In other words, twice as many unmodified MSCs are required to achieve an equivalent in vitro suppressive effect as BUD-Particle MSCs.

As IDO activity is dependent on IFN-γ stimulation, we hypothesized the effect could be further accentuated by pre-activation of MSCs. Activating MSCs with IFN-γ prior to the co-culture enhances IDO expression of the MSCs to maximize potency at the beginning of the assay. This is akin to activating MSCs prior to administration to a patient to maximize potency without relying on the recipient for

Figure 5 | Budesonide particle modification to enable sustained control of MSC phenotype. (A) Fluorescent image of Dil labeled Budesonide PLGA microparticles (Scale bar 5 μm). (B) Physicochemical properties of budesonide PLGA microparticles. (C) Release kinetics of budesonide from 2 mg of PLGA microparticles into PBS at 37°C. (D) MSC association with 1 μm, PLL coated particles was assessed by flow cytometry (Representative plot). (E) Representative confocal image of an MSC modified with 1 μm diameter PLGA particles (white arrows point to red particles) revealing particles are predominately intracellular rather than membrane associated (membrane stained Green, nuclei shown in Blue, scale bar 10 μm). (F) Particle modified MSC viability examined by TUNEL staining. TUNEL stain shown in green with nuclei counterstained with Hoechst (Blue). (bottom) Percent apoptotic cells (mean ± SD, TUNEL+/Hoechst + nuclei, n = 3) shown in each image (Scale bar 50 μm).
activation. Thus, the MSC:PBMC co-cultures were repeated with MSCs preconditioned with IFN-γ for 48 hours to stimulate IDO expression prior to plating in the co-cultures. Pre-activation of MSC IDO expression resulted in similar trends in unmodified MSCs, inferior suppression by Blank-Particle MSCs, and further enhanced BUD-Particle MSCs ability to suppress PBMC proliferation (Fig. 7F,G) and IFN-γ secretion (Fig. 7H) compared to co-cultures with unactivated MSCs.

Next we sought to examine the mechanism responsible for the enhanced suppression. Soluble budesonide released from the MSCs did not appear to be responsible, as PBMCs treated with 1 μM and 10 μM budesonide (no MSCs) were activated to the same degree as untreated PBMCs (Fig. 8A). In order to determine if the enhanced suppressive effect of BUD-Particle modified MSCs can be attributed to IDO or that of other soluble factors, we used a widely used inhibitor of IDO, 1-methyl-DL-tryptophan (1-MT) to inhibit IDO activity. MSC:PBMC co-cultures were repeated at a MSC:PBMC ratio of 1:8 with or without the addition of 1 mM 1-MT. Inhibition of IDO with 1-MT completely abolished BUD-Particle MSCs inhibitory effect suggesting IDO is responsible for the enhanced immunomodulatory potency of BUD-Particle MSCs (Fig. 8B).

Discussion
Herein we have demonstrated MSC immunomodulatory performance can be enhanced through intracellular delivery of steroids. Budesonide treatment resulted in an over 4-fold increase in IFN-γ stimulated MSC IDO activity. Furthermore, budesonide treatment enhanced the expression of IDO in MSCs from multiple donors and restored IDO expression in over-passaged MSCs providing a tool to address donor-donor and passage-passage variability in MSC potency. The enhancement of MSC IDO expression was not limited to budesonide, as similar levels of enhancement were also observed with dexamethasone treatment. Unlike other cell types such as fibroblasts and lymphocytes, MSC viability, metabolic activity, and morphology, were not significantly impacted by exposure to a wide range of budesonide concentrations. In addition to enhancement of
Figure 7 | Engineered MSCs exhibit enhanced immunomodulatory potency. Gating and representative flow cytometry plot of (A) unstimulated and (B) CD3+/CD28+ Dynabead stimulated CFSE stained PBMCs (CFSE vs. Forward Scatter). (C) Representative CFSE vs forward scatter flow cytometry plots of PBMCs harvested from 5 day MSC:PBMC co-cultures. MSC:PBMC ratio and type of MSC particle modification are listed on each column and row respectively. As PBMCs are activated and divide, CFSE is diluted 1:2, resulting in discrete daughter generations that shift to the left with each cell division. (D) Quantification of MSC suppression of PBMCs harvested from three independent donors. Un-stimulated control for each donor used to set threshold for PBMC activation. (E) IFN-γ concentration measured from supernatant of MSC:PBMC co-cultures as marker of PBMC activation. (F) Representative CFSE vs. forward scatter flow cytometry plots of PBMCs harvested from 5 day MSC:PBMC co-cultures containing MSCs preconditioned with IFN-γ to stimulate IDO activity. MSC:PBMC ratio and type of MSC particle modification are listed on each column and row respectively. (G) Quantification of MSC suppression of PBMCs harvested from three independent donors. Un-stimulated control for each donor used to set threshold for PBMC activation. (H) IFN-γ concentration measured from supernatant of preconditioned MSC:PBMC co-cultures as a marker of PBMC activation. Un-stimulated PBMC controls showed no detectable secretion of IFN-γ. (Bars are mean ± SEM, Two-way ANOVA with Tukey correction for multiple comparisons, n = 3, *p < 0.05).
MSC IDO activity, we also observed a reduction in MSC expression of HLA-ABC at all doses in unstimulated conditions and a reduction in HLA-DR expression at high doses in IFN-γ stimulated conditions. The reduced expression of MHC molecules due to budesonide treatment further minimizes the hypo-immunogenic phenotype of native MSC. However, following IFN-γ stimulation the level of HLA-ABC and HLA-DR expression in budesonide treated MSC remains high, and is thus unlikely to significantly alter MSC rejection in allogeneic transplant settings. In fact, previous attempts to shield MSCs from allo-rejection through reduction of HLA-ABC expression required near complete blockade of HLA-ABC presentation in both unstimulated and IFN-γ stimulated conditions by viral immunoevasins. Nevertheless, approaches like this that reduce expression of MHC molecules should be explored further to reduce immunological events following allogeneic transplantation of MSC. Overall, budesonide treatment maintained MSCs proliferative capabilities while reducing MSC’s immunophenotype and greatly enhancing MSC’s immunomodulatory potency through increased IDO activity. To our knowledge, this is the first report of small molecule enhancement of IDO activity in MSCs and the approach represents a significant opportunity to augment MSC-based therapies.

Enhanced expression of IDO was shown to be dependent on both the glucocorticoid receptor and FOXO3, as inhibition of either abrogated the effect. In addition to the current report of FOXO3 enhancement of MSC immunosuppression, enhanced FOXO3 expression has also recently been reported to be a marker of tolerogenic dendritic cells. FOXO3 expressing dendritic cells produce reduced levels of IL-6 and elevated levels of IDO. Inhibition of FOXO3 in tumor associated dendritic cells results in decreased levels of IDO and enhanced anti-tumor immune responses. While these studies have examined the FOXO3-IDO pathway in the context of pathology, we believe there is great potential to leverage the tolerogenic effects to treat graft versus host disease, autoimmune conditions such as Crohn’s and multiple sclerosis, and prevent rejection of transplanted tissues.

As the enhanced immunosuppressive phenotype of MSCs was most prominent in cultures continuously exposed to budesonide (Fig 3E,F), we employed an engineering strategy to establish prolonged control of MSCs. MSCs were engineered with budesonide loaded PLGA particles that continuously release budesonide, resulting in a 5-fold enhancement in IFN-γ stimulated MSC IDO activity. BUD-Particle MSCs were shown to exhibit enhanced immunosuppressive potency in PBMC co-culture assays in an IDO dependent manner. Inhibition of IDO with 1-MT led to abrogation of MSCs’ suppressive potential, implicating IDO as a primary mechanism of budesonide mediated MSC enhancement. BUD-Particle engineered MSCs were twice as potent in suppressing PBMC proliferation and IFN-γ secretion, as determined from ratiometric co-culture experiments. Furthermore, pre-activating MSCs with IFN-γ prior to the co-culture further enhanced their potency. A pre-activation approach could be attractive to maximize the systemic immunomodulatory effects of MSCs, where cells may not come in contact with sufficient levels of IFN-γ to exert their activated systemic effects. In contrast, for local administration of MSCs, pre-activation is likely not necessary as the MSCs will be activated in situ at the site of inflammation. Enhancing the potency of a single MSC enables fewer MSCs to be administered to achieve the same therapeutic effect and enables a single cell to exert a significant impact on its microenvironment. Using the particle-in-cell platform also enables local control of MSC phenotype without requiring soluble glucocorticoid steroids, which in vivo, can contribute to systemic side effects. In addition, this technique can be used to augment the potency of MSCs harvested from different donors and tissues, eliminating the need to select MSCs from only donors or tissues that have high native immunosuppressive potential. Furthermore, as enhanced IDO activity has been shown to lead to tolerance in the setting of pregnancy, solid organ transplantation, and tumor evasion, BUD-PLGA MSCs may be able to extend their therapeutic window by promoting tolerance and evading immune clearance.

In the current study we have demonstrated the utility of BUD-Particle MSCs in in vitro co-cultures. However, the potential benefits of an MSC therapeutic with enhanced IDO expression could be far reaching. This strategy may be used to augment therapeutic potency of MSC therapies by suppressing active inflammation and inducing tolerance in the setting of GVHD, Crohn’s disease, and transplant biology. In addition, modified MSCs with enhanced IDO activity could also be applied to prevent bio-fouling of orthopedic implants and other medical devices due to IDO’s antimicrobial properties. Adaptation of this platform to other cell types to enhance IDO expression (or other immune modulators) for exogenous cell therapy should be possible. We believe steroid preconditioning and especially intracellular engineering strategies present an opportunity to control the therapeutic potency of MSCs and expand the pool of potent cells that can be used for therapies. This may be useful to reduce the number of cells needed for each patient, and ultimately could lead to improved patient outcomes.

**Methods**

**Culture of MSCs.** Primary human MSCs were obtained from Texas A&M Health Science Center, College of Medicine, Institute for Regenerative Medicine at Scott & White Hospital which has a grant from NCRR of the NIH, Grant #P40RR017447

![Figure 8](https://www.nature.com/scientificreports/)  
**PBMC suppression is due to IDO and not soluble budesonide.** (A) Budesonide alone does not suppress CD3/CD28 stimulated activation of PBMCs. Quantification of budesonide mediated suppression or PBMC harvested from three independent donors. Un-stimulated control for each donor used to set threshold for PBMC activation. (Bars are mean ± SEM) (B) Inhibition of IDO abolishes MSC suppression of PBMCs. Quantification of MSC suppression of PBMCs harvested from three independent donors with and without addition of the IDO inhibitor 1-MT. Co-cultures performed with MSCs preconditioned with IFN-γ to stimulate IDO activity at an MSC:PBMC ratio of 1:8. Un-stimulated control for each donor used to set threshold for PBMC activation. (Bars are mean ± SEM, Two-way ANOVA with Tukey correction for multiple comparisons, n = 3, *p < 0.05).
Metabolic activity, viability, and morphology assays. Metabolic activity of MSCs was assessed by MTS (ATCC) following 24, 48, or 72 hour exposure to budesonide. Briefly, 15,000 MSCs were plated in each well of a 96 well plate in 100 μl of culture media containing MDMO vehicle and 0.001, 0.01, 0.1, 1, or 10 μM budesonide. Cultures were maintained for 24, 48, or 72 hours in a humidified culture chamber. Cultures and wells with remaining cell density served as internal controls for each experiment. All conditions were explored in 5 wells for each experiment. To measure metabolic activity, 50 μl of activated MTS reagent was prepared and added to each well per manufacturer’s instructions. The plate was incubated for 3 hours and read at 490 nm and 630 nm for reference. To determine the morphology and viability of budesonide treated MSCs, 30,000 cells were plated into each well of a 24 well plate with vehicle or 0.001–100 μM budesonide supplemented culture media. Cells were grown for 24, 48, or 72 hours. Before harvest, 4 random fields of each well were imaged at 10× using an inverted phase contrast microscope to capture cell morphology and differences in cell proliferation. To determine viability, cells were then harvested with Accutase, washed, and re-suspended in 100 μl of solution containing 1% FITC-Annexin V and 5 μl propidium iodide (Invitrogen) and stained on ice for 15 min. Cells were washed with 400 μl PBS, centrifuged, re-suspended in fresh PBS and analyzed by an Accuri C6 flow cytometer. MSCs treated with staurosporine to induce cell death were used as a positive control for each experiment. TUNEL staining of budesonide treated and particle exposed MSCs was performed according to the manufacturer’s instructions using a in situ cell death detection kit-fluorescin (Roche) to label double strand DNA breaks indicative of apoptosis and counterstaining nuclei with Hoescht (Invitrogen). Fixed, DNase treated MSCs (300 U/ml DNase, 1 mg/ml BSA, in 50 mM TrisHCL for 10 min at room temperature) were used as a positive control for double strand DNA breaks. Imaging (NIH) was used to quantify the number of dual stained nuclei, all conditions were performed in triplicate.

Flow Cytometry. Expression of MHC molecules on MSCs following 24 hour preconditioning or continuous exposure to various doses of budesonide was determined using an Accuri C6 flow cytometer. For each condition, MSCs were grown in T25 flasks, harvested with Accutase, washed, and split for staining with either Alexa Fluor 488 anti-human HLA-ABC and Alexa Fluor 647 anti-human HLA-DR or isotype controls. Cells were re-suspended in antibody solution in PBS + 1% BSA and stained on ice for 15 min. Cells were washed with 400 μl PBS, centrifuged, and analyzed by flow cytometry. Mean fluorescence intensity (MFI) was determined using CFlow software.

IDO Activity Assay. MSC cultures were grown to 80% confluence in T75 flasks. Cells were washed with PBS, harvested with Accutase cell dissociation reagent (Invitrogen), centrifuged, counted, and resuspended in 300 μl of ice cold PBS (without CaCl2/MgCl2 ions) with 0.1% (w/v) Triton X-100. Cell suspensions were lysed through triplicate freeze thaw cycles, and briefly pulse sonicated using a probe sonicator with power output of 3 W. Lysates were centrifuged at 25000 x g for 4 min. 250 μl of sample supernatant, reconstituted recombinant human IDO (rhIDO), or L-kyurenine standard were mixed in a 1:1 ratio with 250 μl of IDO buffer (40 mM ascorbic acid, 20 mM methylene blue, 200 μg/ml catalase, 800 mM L-trytophan, in 50 mM MES buffer, pH 6.5). Samples were incubated at 37°C for 45 min, followed by addition of 100 μl of trichloroacetic acid (30%, v/v) and incubated at 52°C for 30 min. Samples were centrifuged at 25000 x g for 10 min to remove proteins, and 100 μl of the resultant supernatant for each sample was added to a 96 well plate (all samples and standards measured in duplicate). 100 μl of Ehrlich’s reagent (0.8% p-dimethylaminobenzaldehyde in glacial acetic acid) was added to each well to induce a color change. Samples were incubated at room temperature for 10 min and then read on a microplate reader at 490 nm. rhIDO was used as a positive control in each assay and an internal L-kyurenine standard (8–500 μM) was included to determine kyurenine production of IDO from MSC lysate.

Budesonide Particle Production. PLGA particles were formulated using an oil-in-water single emulsion technique. 10 KDa molecular weight 50:50 poly(lactic-co-glycolic acid) and a carbohydrate group (Intralipid, 20%) with budesonide microparticles (1:100) was obtained from Lactel Absorbable polymers. 50 mg of PLGA, 8 mg of budesonide, and 10 μl of Dil, were dissolved in 2 ml of dichloromethane in a glass vial. After dissolving, PLGA:Drug solution was probe sonicated for 30 seconds to thoroughly mix the drug within the polymer. The solution was then added drop wise to 20 ml of filtered 1% (w/v) polyvinyl alcohol (80% hydrolyzed, Sigma) on ice with slow stirring and homogenizing at 33,000 rpm using a Tisswe Master 125 homogenizer (Omni International). After 2 min homogenization, particles were gently stirred in a chemical hood for 4 hours to allow for complete dissolution of solvent. Suspensions were then centrifuged, and washed with distilled water 3 times before lyophilization and characterization. Blank particles were formed in parallel by omitting the addition of budesonide in the above procedure. The zeta-potential of particles was modified through adsorption of poly-L-lysine (PLL). Briefly, 6 mg/ml particle suspensions were prepared in 100 μg/ml PLL solution in distilled water and gently agitated for 2 hours. Particles were then frozen for subsequent use. The hydrodynamic diameter, polydispersity, and zeta potential of particles was measured in distilled water using a Malvern Zetasizer ZS90. Averages from three separate samples are reported. In addition, 40% fluorescence microscopy images were acquired to confirm the size and polydispersity of the particle suspensions.

Budesonide Particle Loading and Release Kinetics. High pressure liquid chromatography (HPLC) was used to determine the drug loading, encapsulation efficiency, and release kinetics of the budesonide microparticles. To determine drug loading, 2-3 mg of particles were weighed into Eppendorf tubes, quickly spun into a pellet, and swollen by addition of 500 μl methanol. Samples were agitated at 37°C for 2 hours to allow for complete release of budesonide from the particles. Samples were then filtered to remove unbound drug and then lyophilized to dryness and re-suspended in 1 ml of 1% DMSO. rLPS were used as an Agilent 1100 series HPLC. An Agilent Zorbs Eclipse XDB-C18 column (4× 250 mm, 5 μm) was used with a mobile phase composed of 70:30 acetonitrile:0.1% acetic acid, 25 μl injection volume, and 1 ml/min flow rate. Budesonide was detected by peak absorbance at 248 nm and quantified by comparison to internal standard curve.

Drug loading was calculated as the dry mass of drug per mg of PLGA particles. Encapsulation efficiency was calculated as the ratio of encapsulated drug to total drug added to formulate particles. All samples were prepared in triplicate. Release kinetics were determined by suspending 2 mg of particles in 200 μl of PBS placed in a 2 inch section of 6–8,000 molecular weight cut dialysis bag (Spectra Labs). Dialysis bags were submerged in 40 ml of PBS to simulate infinite sync conditions and agitated at 37°C. At each time point, 1 ml of PBS was collected and replaced with fresh PBS. Samples were frozen until HPLC analysis using the method as described above. All samples were prepared in triplicate.

Particle Modification of MSCs. MSC particle modification was performed as previously described4. Briefly, MSCs were cultured to 80% confluence prior to particle modification. PLL coated budesonide or blank particles were thawed, briefly sonicated to break up particle clumps, and suspended in 1% supplement Stempro complete medium to make 10 mg/ml particle solution of each batch. FL2-H7 labeled particles were modified at the end of the day and incubated with particle media overnight. Following particle modification, MSCs were washed three times with PBS, provided with fresh full supplement culture media and allowed to rest for 24 hours before subsequent experimentation. To confirm particle internalization, confocal microscopy was performed as previously described4.

PBMC Isolation from whole blood. Fresh whole blood from 3 donors was collected, after informed consent was obtained, from Research Blood Components for each experiment (Watertown, MA). Upon delivery, blood was diluted 1:1 with sterile
PBS/- supplemented with 2% fetal bovine serum, layered on top of Ficoll-Paque Premium (GE Healthcare), and centrifuged at 400 rcf for 30 min with the brake off. The buffy coat was collected and washed with PBS:FBS solution. PBMCs were counted and either used immediately or frozen in freezing media (RPMI supplemented with 10% DMSO, 40% FBS, 1% Penicillin/Streptomycin, 1% L-Glut).

MSC/PBMC Co-cultures. The ratio of MSCs to PBMCs was established by adding 260,000 PBMCs and 65,000, 32,500, or 16,250 MSCs to each well of a 24-well plate. MSCs were particle modified and allowed to rest a day before the co-culture experiments. Unmodified, blank-particle modified, or bud-particle modified MSCs were plated in 24 well plates and allowed to adhere. PBMCs labeled with a CellTrace CFSE Cell Proliferation Kit (Invitrogen) according to the manufacturer’s instructions. 260,000 PBMCs were then added to each well. To stimulate PBMCs proliferation, 260,000 CD3+ /CD28+ Dynabeads (StemCell Technologies) were also added to each well. Total culture volume of each well was standardized to 0.5 ml of RPMI supplemented with 10% FBS, 1% (v/v) L-Glutamine 1% penicillin/streptomycin. PBMCs stimulated with Dynabeads but without MSCs were used as an activated control and un-stimulated PBMCs grown without MSCs were used as an un-activated control for each donor (Fig 7A,B). Co-cultures were maintained for 5 days after which the media from the wells (containing PBMCs) was collected and centrifuged to pellet the PBMCs. The conditioned media was then collected for subsequent analysis. PBMC pellets were re-suspended in PBS/- containing 1% FBS and PBMC proliferation was assessed by flow cytometry. Un-stimulated PBMC controls were used to set the threshold for PBMC activation for each donor. To inhibit IDO activity, the MSC/PBMC co-cultures were repeated with or without the addition 1 mM of the enzymatic inhibitor 1-methyl-DL-tryptophan (1-MT, Sigma) prepared in RPMI media. Data was analyzed using Accuri’s CFlow software. IFN-γ content of co-culture supernatant was determined using an ELISA MAX Deluxe Human IFN-γ kit (Biolegend) by comparing to internal standards according to manufacturer’s instructions.

Statistical Analysis. All statistics were performed using Prism 6 (GraphPad). Two-way ANOVA’s were performed on data sets with two independent variables (dose and time or MSC group and MSC:PBMC ratios) and one-way ANOVA was performed on data sets with a single independent variable (effect of budesonide conditioning on MSC IDO activity). Fisher’s LSD test without correction for multiple comparisons was used when assessing effect of budesonide doses on MSC metabolic activity and viability as the test has a higher Type I error and would therefore highlight any potential negative impact of budesonide on MSCs that would require further evaluation. Bonferroni correction for multiple comparisons, which is a more conservative test than the Fisher’s LSD method, was used for the MHC expression data as all comparisons were made with respect to the untreated control. For all other statistics, the mean of all groups were compared to all other groups and thus, Tukey correction for multiple comparisons was used to minimize Type I error.


**Acknowledgments**

This work was supported by National Institutes of Health grant HL095722, a Department of Defense grant # W81XWH-13-1-0305, and by a Movember Prostate Cancer Foundation Challenge Award to J.M.K. J.A.A. was supported by the Hugh Hampton Young Memorial Fellowship. We would also like to thank Prof. Dan Anderson of MIT and Dr. Augustine Chot of Weill Cornell Medical College for their constructive feedback on the manuscript.

**Author contributions**


**Additional information**

Competing financial interests: J.M.K. is a paid consultant for Sanofi and Stempeudics.